CRO Partnerships Target CRO partnerships in cardiovascular safety and drug safety studies to deploy VivaQuant’s turn-key ECG analysis and arrhythmia liability services, tapping into pharma and contract research organizations that need robust, scalable data from ambulatory ECGs.

Proprietary Advantage Promote the proprietary MDSP denoising technology that removes the majority of noise while preserving signal fidelity, enabling high-quality measurements from noisy ambulatory ECG data and supporting regulatory-grade analyses; use the patent as a differentiator in proposals.

Product Suite Leverage the existing product suite including RX-1 mini and AE-1010 Rhythm Express to offer bundled solutions combining software tooling with services, creating upsell opportunities for labs and CROs seeking repeatable ECG workflows.

Industry Credibility Capitalize on industry recognition and IP strength to build credibility with large pharma and device manufacturers, using Tekne Award finalist status and the Physiological Signal Denoising patent in pitches and RFPs.

Growth Opportunities Growth-ready, US-based boutique provider with a focused offering and scalable capabilities, presenting a compelling option for near-term sales to national and regional pharma hubs and CRO networks seeking specialized ECG analytics and efficient study timelines.